Budakeszi, Hungary

György István Lévay

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: György István Lévay: Innovator in Pharmaceutical Chemistry

Introduction

György István Lévay is a notable inventor based in Budakeszi, Hungary. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on thiadiazine derivatives. His research focuses on developing compounds that can modulate the activity of the α7 nicotinic acetylcholine receptor, which has implications for various therapeutic applications.

Latest Patents

Lévay holds a patent for his invention related to thiadiazine derivatives. This patent encompasses not only the derivatives themselves but also their pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates, and hydrates. The pharmaceutical compositions containing these compounds are designed for use as modulators of α7 nicotinic acetylcholine receptor activity in mammalian subjects.

Career Highlights

Lévay is associated with Richter Gedeon Nyrt., a prominent pharmaceutical company in Hungary. His work at the company has allowed him to contribute to the development of innovative pharmaceutical solutions. His expertise in the field has positioned him as a valuable asset in the research and development of new therapeutic agents.

Collaborations

Lévay has collaborated with notable colleagues, including István Ledneczki and János Éles. These collaborations have fostered a productive environment for innovation and have led to advancements in their shared research interests.

Conclusion

György István Lévay is a distinguished inventor whose work in pharmaceutical chemistry has the potential to impact therapeutic practices significantly. His contributions, particularly in the area of thiadiazine derivatives, highlight the importance of innovation in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…